Core One LabsCSE: COOL
Data updated
Enterprise Intelligence
Quarterly psychedelic drug-development briefing
Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.
Canadian biotech developing biosynthetic psilocybin through its Vocan Biotechnologies subsidiary. Vocan's proprietary fermentation-based process produces pharmaceutical-grade psilocybin without mushroom cultivation. Signed a partnership with Cube Psytech for psychedelic drug development in December 2023.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 1
- Active programmes
- 1
- Lead stage
- Preclinical
- Forecast coverage
- 1 of 1
All tracked candidates active
All tracked programmes active
Current furthest stage
1 active programme with forecast fields
Latest sourced update
Sep 20, 2025 - Regulatory filing - Canadian Securities Exchange - Vocan Biosynthetic Psilocybin / Vocan Biosynthetic Psilocybin Platform — DEFUNCT
Next known catalyst
No next milestone forecast yet.
Development Programmes
1Vocan Biosynthetic Psilocybin
PsilocybinMental health (psilocybin API supply) — programme abandoned
Major Depressive Disorder (MDD)
Company delisted from CSE September 2025; entire board resigned May 2025; programme abandoned
Milestones
preclinical-data
CancelledWhy it matters: Core One Labs' Vocan platform used engineered yeast fermentation to produce pharmaceutical-grade psilocybin. The company never advanced beyond preclinical/platform stage.
Company milestone
CompletedActual: Feb 1, 2024
Core One Labs enters default status with British Columbia Securities Commission (BCSC); BCSC prevented proposed equity financing critical to operations
Why it matters: Regulatory default blocked the company's ability to raise capital, effectively ending its pipeline ambitions. The BCSC action precipitated the company's collapse.
Company milestone
CompletedActual: Aug 1, 2024
Core One Labs suspended from CSE trading (Bulletin 2024-0804)
Why it matters: Trading suspension followed the BCSC default, further isolating the company from capital markets.
Company milestone
CompletedActual: May 1, 2025
Entire board of directors and executive management resign
Why it matters: Mass resignation signals complete abandonment of the company. No successor management was appointed.
Company milestone
CompletedActual: Sep 19, 2025
Common shares delisted from CSE (Bulletin 2025-0920)
Why it matters: Final corporate death. Core One Labs held 4 provisional patents via Akome Biotech and 3 via Awakened Biosciences — IP status unknown post-delisting.
Recorded Events
Sep 19, 2025: Company milestone
May 1, 2025: Company milestone
Aug 1, 2024: Company milestone
Feb 1, 2024: Company milestone
Quick Facts
- Type
- Public Biotech
- Ticker
- CSE: COOL
- Lead Stage
- Preclinical
- Website
- Visit